Bristol-Myers Squibb Company (BMY)
Pre-Market:
| Previous Close | 48.99 |
| Open | 49.00 |
| Bid | 49.05 x 800 |
| Ask | 48.90 x 1400 |
| Day's Range | 48.55 - 49.04 |
| 52 Week Range | 47.58 - 69.10 |
| Volume | |
| Avg. Volume | 15,456,937 |
| Market Cap | 99.027B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 12.66 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.40 (4.91%) |
| Ex-Dividend Date | Apr 04, 2024 |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue. The New Jersey-based drugmaker posted a loss of $4.40 per share, including charges for acquired research and development. On a net basis, Bristol's loss was $5.89 per share.
- Investor's Business Daily
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
- Reuters
Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue. The New Jersey-based drugmaker posted a loss of $4.40 per share, including charges for acquired research and development. On a net basis, Bristol's loss was $5.89 per share.
